ReviewFrontiers in immunology2021
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 2 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Pooled it
- Blood cell counts can predict adverse events of immune checkpoint inhibitors: A systematic review and meta-analysis.Frontiers in immunology · 2023Pooled it
- Laboratory Medicine in Immune Checkpoint Inhibitor-Induced Autoimmune Disorders: Baseline Assessment, Diagnostic Algorithms, Monitoring, and Predictive Biomarkers.Annals of laboratory medicine · 2026Review
- PD-L1-Inhibitor-Associated Hidradenitis Suppurativa.Journal of cutaneous pathology · 2026Article
- Microbial Influence on Immune Checkpoint Inhibitor Therapy in Non-Small Cell Carcinoma: The Gut-Lung-Immune Axis.Cancers · 2026Review
- The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.Internal medicine (Tokyo, Japan) · 2026Article
- Immune-Mediated Colitis Induced by Immune Checkpoint Inhibitors: Pathophysiology, Clinical Management, and the Emerging Role of Fecal Microbiota Transplantation.Biomedicines · 2026Review
- Histologic Features of Melanocytic Nevi Secondary to Melanoma Treatment With Immune Checkpoint Inhibitors.Cureus · 2026Article
- Enhancing Immunotherapy in Lung Cancer: The Promise of dMMR/MSI-H Tumors and Immune Checkpoint Inhibitors.Health science reports · 2026Article
- Upadacitinib for anti-TNFα refractory immune checkpoint inhibitor-induced colitis: a case report.Therapeutic advances in gastroenterology · 2026Article
- Single-cell transcriptomic insights into the immune heterogeneity of immune checkpoint inhibitors related organ toxicities.Frontiers in immunology · 2026Review
- Toward nursing-integrated biomarker surveillance for immune-related adverse events during immune checkpoint inhibitor therapy.Frontiers in medicine · 2026Review
- Efgartigimod in the treatment of immune checkpoint inhibitor-related myasthenia gravis -myositis overlap syndrome: a case report.Frontiers in immunology · 2026Article
- Can tissue immune states shape the risk of hyperprogressive disease?Frontiers in immunology · 2026Review
- Machine learning identifies a distinct microbiota signature in immune checkpoint inhibitor colitis compared with inflammatory bowel disease.The oncologist · 2025Article
- Article
- Parenteral Nutrition in Patients with Incurable Cancer: Exploring the Heterogenous and Non-Randomised Clinical Landscape.Current oncology (Toronto, Ont.) · 2025Article
- Single-cell hdWGCNA identifies ICI-related-colitis key CD8 + T cells linked to immunotherapy response and prognosis in colon cancer.Discover oncology · 2025Article
- Lack of phospho-eIF4E worsens experimental colitis by inhibiting Treg suppressive activity.Journal of inflammation (London, England) · 2025Article
- Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases.Histopathology · 2025Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs), as one of the innovative types of immunotherapies, including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors, have obtained unprecedented benefit in multiple malignancies. However, the immune response activation in the body organs could arise immune-related adverse events (irAEs). Checkpoint inhibitor colitis (CIC) is the most widely reported irAEs. However, some obscure problems, such as the mechanism concerning gut microbiota, the confusing differential diagnosis with inflammatory bowel disease (IBD), the optimal steroid schedule, the reintroduction of ICIs, and the controversial prognosis features, influence the deep understanding and precise diagnosis and management of CIC. Herein, we based on these problems and comprehensively summarized the relevant studies of CIC in patients with NSCLC, further discussing the future research direction of this specific pattern of irAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.